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Abstract
Clinical practice guidelines are one of the foundations of efforts to improve health care. In 1999, we authored a
paper about methods to develop guidelines. Since it was published, the methods of guideline development have
progressed both in terms of methods and necessary procedures and the context for guideline development has
changed with the emergence of guideline clearing houses and large scale guideline production organisations (such
as the UK National Institute for Health and Clinical Excellence). It therefore seems timely to, in a series of three
articles, update and extend our earlier paper. In this first paper we discuss: the target audience(s) for guidelines and
their use of guidelines; identifying topics for guidelines; guideline group composition (including consumer
involvement) and the processes by which guideline groups function and the important procedural issue of
managing conflicts of interest in guideline development.

Background
Clinical practice guidelines (hereafter referred to as guidelines) are one of the foundations of efforts to improve
health care. The modern age of guidelines began with a
1992. Institute of Medicine report, which defined guidelines as “systematically developed statements to assist
practitioner and patient decisions about appropriate
health care forspecific clinical circumstances”.[1] In 1999,
we authored a paper about methods to develop guidelines.
[2] It covered: identifying and refining the subject area of
the guideline; running guideline development groups;
identifying and assessing the evidence; translating evidence into a clinical practice guideline; and reviewing and
updating guidelines. Since it was published, the methods
of guideline development have progressed both in terms
of methods and necessary procedures and the broad context for clinical practice guidelines has changed.
To help users identify and choose guidelines there has
been the emergence of guideline clearing houses (such
* Correspondence: shekelle@rand.org
4
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as the AHRQ Guideline Clearing House (www.guideline.
gov)) that identify and systematically characterize guidelines on a number of domains and the development of
robust guideline appraisal instruments such as the
AGREE tool [3,4] There has been the appearance of
large scale guideline production organisations both at a
national level (such as the UK National Institute for
Health and Clinical Excellence or. Scottish Intercollegiate
Guidelines Network) and a condition level (such as the
Ontario Cancer Guideline Program). There have also been
relevant reports (that some of us have participated in) for
the World Health Organisation [5]and professional societies (Schünemann HJ, Woodhead M, Anzueto A, Buist
AS, MacNee W, Rabe KF, Heffner J. A guide for guidelines
for professional societies and other developers of recommendations: an official American Thoracic Society (ATS)/
European Respiratory Society (ERS) Workshop Report;
forthcoming). Such organizations and those interested in
producing and using guidelines now have a high profile
society in the Guidelines. International Network (http://
www.g-i-n.net/). Against this background it seems timely
to, in a series of three articles, update and extend our earlier paper on the methods of developing clinical practice
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guidelines. This series is based on a background paper [6]
prepared for the Institute of Medicine report “Clinical
Practice Guidelines We Can Trust” [7].
In this first paper we discuss: the target audience(s) for
guidelines and their use of guidelines; identifying topics
for guidelines; guideline group composition (including
consumer involvement) and the processes by which
guideline groups function and the important procedural
issue of managing conflicts of interest in guideline development. Inthe second paper we will move on to discuss
issues of identifying and synthesizing evidence: deciding
what type of evidence and outcomes to include in guidelines; integrating values into a guideline; incorporating
economic considerations; synthesis, grading, presentation of evidence; and moving from evidence to recommendations.Finally, in the third paper we will discuss the
issues of: reviewing, reporting, and publishing guidelines;
updating guidelines; and the two emerging issues of enhancing guideline implementability and how guideline
developers should approach dealing with the issue of
patients who will be the subject of guidelines having comorbid conditions. By updating our previous work we
hope to offer to a general reader a useful current overview of the main methodological and procedural issues
in guideline development.
Target audiences and their use of guidelines

An important first step in developing a guideline is to
clarify the target audience. A clear sense of the target
audience informs subsequent decisions about the guideline’s scope, objectives, and format and style of wording.
Typically, guidelines have both primary and secondary
audiences. The primary audience is the category of clinicians (and patients) for whom the guideline is nominally
intended and who are most likely to use the guideline in
patient care settings. However, guideline developers
often recognize a secondary audience that takes considerable interest in the recommendations. For example, a
family medicine or paediatrics society may develop
guidelines for its practitioners, knowing that other primary care professionals could refer to the guidelines in
managing the same condition. Guideline developers are
also aware that their recommendations may be used in
policy processes such as informing coverage decisions by
healthcare providers, insurers and employers’ benefits
packages.
Guidelines often inadvertently focus on physicians as
the target audience and use the term “physician” or
“doctor” in lieu of “clinician,” but the topics they address
may be equally relevant to a wider range of clinicians.
For example, a guideline on a primary care chronic disease management topic (such as diabetes mellitus) will
be relevant not only to primary care physicians but also
to nurse practitioners, physician assistants, and other
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clinicians or social workers who work in primary care
settings. Even when the target audience is clearly physicians, it is useful to clarify the type of physician(s) for
whom the clinical practice guideline is primarily intended.
Guidelines intended for primary care physicians may include content of less interest to specialists, and vice versa.
Guidelines on a highly specialized procedure, performed
only by sub-specialists, are unlikely to be used by primary
care physicians and therefore need not review basic background on the health condition, can focus on narrow
evidence questions, and can use specialized terminology
without extensive elaboration.
Prioritizing topics for guideline development

There are many factors that influence the choice of
topics for the development of guidelines including scientific criteria set alongside the needs of health care policymakers, specialty society professional identification, and
in response to popular media coverage of certain high
profile cases. Guidelines can be developed around conditions (diabetes, hypertension, HIV infection, etc.) or
around procedures (coronary angiography, colonoscopy,
carotid endarterectomy, etc.) The choice has to do with
the target audience and the need. Most guidelines are
developed for conditions. Among the scientific factors
are the criteria in Table 1.
Thus, situations for the development of guidelines are
often considered to be those conditions which are common, costly, have large effects on premature mortality or
morbidity, for which there is good evidence that appropriate health care can make a difference in outcomes,
and for which we know that there are wide variations in
current care (as a proxy for professional uncertainty
about how to care for the condition) or prima facie
knowledge that current care does not meet some wellaccepted standards. Clearly, judgment is needed in applying these criteria. There are some conditions that are
rare, but for which receiving appropriate medical care is
the difference between a normal health outcome and catastrophe (e.g. phenylketonuria). Such conditions should
not be dismissed as a low priority for guidelines based
solely on prevalence. Similarly, there are some conditions which have only modest effects on morbidity, but
which are so common that the cumulative effects of appropriate management at a population level may be large
Table 1 Criteria for developing guidelines
•

High prevalence condition or high use medical procedure

•

High associated cost

•

Effects on premature mortality and avoidable morbidity

•

Evidence that medical care can make a difference in outcomes

•

Knowledge of current variations in practice, or that practice does not
match some known practice parameters
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(e.g. acute pharyngitis). Also, the evidence that differences in clinical management lead to differences in
health care outcomes does not necessarily have to be
positive - for some conditions, too much health care
might produce negative individual health or population
outcomes (e.g. treating acute upper respiratory infections with antibiotics may cause patients to have antibiotic associated diarrhea or may increase community
antibiotic resistance rates).
Most often the decisions about the relative importance
of prevalence, cost, effect of health care, etc., are made
implicitly; there is little published about how such decisions are made. The US Preventive Services Task Force
(USPSTF) has a Topic Prioritization Workgroup that
regularly assesses nominations for guidelines that come
from professional societies and other groups.[8] The
USPSTF does not use a formal scoring system, but rather assesses each topic as a whole, using criteria similar
to that presented above, as do NICE and SIGN in the
UK. The American College of Physicians Clinical Guidelines Group likewise uses a global judgment method for
prioritizing topics [9].
Guideline group composition and group process

Guideline development involves both a technical process
(systematic reviews of relevant evidence) and a social
process (interpretation of the results of the systematic
review and development of recommendations). The validity of guideline recommendations can be adversely
influenced if either process is biased. While there has
been considerable methodological focus on ensuring the
validity of the technical process, less attention has been
paid to optimizing the social process.[10-14] The quality
of the social process is dependent upon the composition
of the group (whether the right people have been brought
around the table) and the group process (whether the
process allows all to participate in a constructive discussion around the implications of the evidence).
Group composition

There is consistent empirical evidence that the composition of recommendation making groups influence the
resulting recommendations. Hutchings and colleagues
completed a systematic review of factors affecting judgments produced by formal consensus development
methods.[15] They identified 22 studies that examined
the impact of specialty or profession of individual participants and observed that participants that performed a
procedure were likely to rate more appropriate indications for that procedure. They also identified five studies
that compared the recommendations made by unidisciplinary and multi-disciplinary groups; in all studies,
recommendations by multidisciplinary groups were
more conservative. While there is no gold standard to
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compare with, these studies are usually interpreted to
support the use of multidisciplinary recommendation
groups. Lomas identified three reasons in support of this:
firstly, the limited information available for guideline development needs to be supplemented by the interpretations of these stakeholders; secondly, legitimate conflicts
over values need to be resolved; and thirdly, the successful
introduction of a guideline requires that all key disciplines
contribute to its development to ensure "ownership" and
support.[16] Given these empirical and theoretical arguments, there is a broad international consensus that
guideline development groups should be multidisciplinary
with representation from key stakeholder groups.
The number of group members and the balance of disciplines should be influenced by the focus of the guidelines. When deciding on the composition of the group,
all potential stakeholders should be identified including:
health care professionals who are directly involved in the
clinical management of patients in different health care
settings (for example, primary and secondary care), policy
makers who may need to make decisions about resource
utilization and patients. There then has to be made a decision about which categories of participant to involve
within the guideline group. Guideline developers often
have to weigh the desire for wide representation against
the need for a cohesive working group. Small groups may
not have sufficient experience within their members; larger groups may lack cohesiveness and be difficult to lead.
In general, the optimum size for a small group is thought
to be between eight and ten people, although groups of
larger size have operated effectively.
Consumer involvement in clinical practice guideline
development

There is an increasing (though still limited) literature on
consumer involvement in health decision making in general. A systematic review of patient and public involvement programs (PPIPs) in developing clinical practice
guidelines [17] looked at stated reasons for including
patients and the public within the process. Of 71 descriptive reports (guideline documents or methods reports,
evaluative studies) included in the review 23 reported
using PPIPs to “incorporate patients’ values, preferences,
knowledge, or perspectives in CPG recommendations”.
Other stated reasons were to “improve the implementation of the CPG (7/71), increase the comprehensiveness of
the CPG (7/71), promote patients’ or the public’s influence
over the CPG development process (7/71), and adapt
CPGs to the target population (5/71)”.
These issues are reflected in the empirical work of
Boivin et al. [18] who, from 18 interviews with patients,
health professionals, and public health experts, identified
four discourses about including patient preferences in the
process of guideline development. Firstly a Governance
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discourse (concerned with maximizing public health benefits); secondly an Informed discourse (concerned with
maximizing consumer choice via information on benefits
and harms); thirdly a Professional Care discourse (concerned with individualizing clinical decisions to individual
patients); and a Consumer Advocacy discourse (concerned
with optimizing consumers political power within the
process). The systematic review by Legare [17] represents
the most comprehensive analysis of consumer involvement to date though the literature is descriptive. Of the 71
reports included only 28 were dealing with consumers
within the guideline development group itself and only 29
were dealing with consumers involved in crafting recommendations. Other methods of consumer involvement
included workshops/meetings/seminars, involvement in
systematic reviewing, focus groups, individual interviews
and public polls/surveys. Across the reports the authors
identified a number of barriers to consumer involvement the discrepancy between the views of patients and experts,
challenges of recruitment, obtaining representative input,
consumers lack of familiarity with technical issues and the
degree of work/time involved. Against these they set the
positive impact of training and support.
From the review it appears that there are still few analytical empirical accounts of attempts to involve consumers in guideline development, and there are no robust
evaluations of the effectiveness of different methods. A
systematic review of the effectiveness of consumer involvement in health decision making [19] only identified
six randomized controlled trials in total and did not find
any studies in the context of clinical guideline development (despite searching).
Williamson [20] has proposed three types of patient
representatives, depending on the contributions and
skills that each can bring: (a) fellow patients who would
mainly present their own views, (b) a member of a patient group who presents the organization’s position, and
(c) patient advocates who present knowledge of patient
views. The North of England Evidence Based Guideline
Development Program described their experience of four
methods of consumer involvement (three of which were
based within the process of guideline development and
one of which was conducted to explore the potential of
the method for future use) [21]. They included:
 incorporating individual patients in guideline

development groups;
 a ‘one off ’ meeting with patients;
 a series of workshops with patients;
 incorporating a consumer advocate in guideline

development groups
Individual patients who participated in a guideline development group contributed infrequently and had problems
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with the use of technical language. Although they contributed most in discussions of patient education, their contributions were not subsequently acted on. Within a ‘one off’
meeting with a group of patients, participants again
encountered problems with medical terminology and were
most interested in sections on patient education and self
management. Their understanding of the use of scientific
evidence to derive more cost-effective care practices was
unclear. The workshop format was relative resource intensive but made it possible to explain the technical elements
of guideline development, enabling patients to engage in
the process and make relevant suggestions. A patient advocate who served on a group felt confident to speak and
was accustomed to discussions with health professionals
and to medical terminology.
However, the involvement of lay people in practice
guideline development can also be problematic. The
North of England experiences and Legare’s review [17]
demonstrated the challenges of the lack of consumers’
training and scientific literacy (though this can apply in
degree to many other guideline group members). Another
challenge with consumer involvement occurs when the
representative has a visceral personal experience with the
disease or an advocacy role that interferes with the ability
to examine the evidence and recommendations dispassionately. Such individuals may have difficulty divorcing
their personal narrative or policy agenda from the systematic methods and analytic rules a practice guideline group
should follow. As a consequence, the group’s orderly review of the evidence and construction of recommendations can be sidelined by the objections and testimonials
of the consumer representative.
Several strategies exist for maximizing the benefits of
consumer engagement while avoiding the difficulties.
For example, as should occur with selecting any member
of a practice guideline group, selection criteria can be
applied in choosing a consumer representative with the
ability to consider the evidence objectively and make
recommendations that depart from preconceived views
or self interests. The National Institute for Health and
Clinical Excellence in the United Kingdom advocates the
involvement of at least two consumers on guideline development groups and provides induction sessions that
brief consumers on what to expect as participants.
Another option is to not seat a consumer representative on the guideline group itself, limiting the latter to
professionals, but eliciting the perspective of patients
and the public as part of a larger stakeholder input exercise. For example, a group may not include a consumer
representative but may invite patients or other laypersons to review draft documents or attend a group meeting to share their perspective. Guidelines groups can
host an open forum, in which various stakeholder
groups, such as patients, payers, manufacturers, and
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professional associations, are afforded the opportunity to
express their perspectives and criticisms, present scientific evidence of relevance to the guideline, or raise concerns about the impact or implementation of proposed
recommendations [22]. The advantage of this approach
is that it exposes the group’s deliberations to concerns
and information that it might otherwise overlook and
provides stakeholders a sense of “being heard,” but it
leaves the group the freedom to then deliberate privately
in processing the comments.
Guideline group processes

A range of psychosocial factors can influence the progress
and content of group meetings.[10] Guideline development
groups undergo a socialization process (forming, storming,
norming, performing, adjourning).[23] For example, during
the first few meetings of a group, much attention may be
paid to the development of good interpersonal relations,
establishing group aims, developing norms of behavior and
exploring explicit and implicit roles. Such group-related
issues may have to be addressed before substantial progress
can be made on the development of clinical recommendations. Group decision-making essentially involves three
phases: orientation (defining the problem), evaluation (discussion of decision alternatives), and control (deciding
which of the alternatives is to prevail).[24] Ideal conditions
for group decision-making are those which enable the
views of all parties to be expressed and considered before a
recommendation that is acceptable to the majority is
reached.[10] Dysfunctional group processes that allow undue influence of minority or majority views may result in
the production of invalid or unreliable recommendations.
Examples include minority influence, group polarization
and groupthink.[10] Multidisciplinary groups are particularly at risk in this regard, since their members vary in professional status, in the nature or depth of their specialist
knowledge and in their appreciation of the roles and modus
operandi of their professional colleagues.
The risk of such psychosocial biases can be reduced
with careful planning and attention to small group processes. For example, it may be appropriate to ensure that
guideline development groups receive support to ensure
that the group both functions effectively (the group
process) and achieves its aims (the group task).[25] It is
possible for a single individual to be responsible for supporting both the group process and the group task. If a
group is particularly large or if the task is particularly
complex, however, such leadership roles may be better
divided between two individuals, providing that both
they and the group are clear about their differing functions. Technical support is required mainly to identify
and synthesize evidence and present this to the group in
a form that allows them to make recommendations. This
needs a range of skills more likely to be found within
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researchers than clinicians. During guideline development, the person(s) responsible for technical support
should encourage the group to scrutinize the guideline
repeatedly to ensure its internal logic and clarity.
Managing conflicts of interest in guideline development
What are conflicts of interest?

An aspect that has gained increasing prominence with
the “industrialisation” of guideline development is the
need to consider conflicts of interest. Financial, intellectual and other investments in aspects of health care can
result in biased judgement about a topic of interest; a
concept that is generally called “conflict of interest”. A
number of organizations have defined “conflicts of interest” (COI) (Table 2). Grilli and co-workers evaluated 431
practice guidelines developed by specialty societies and
found that 67% did not report the type of professionals
involved in the guideline development.[26]. Therefore, an
assessment of the potential influence of COI would not be
possible. A study in the journal Nature of over 200 guidelines listed in the US National Guideline Clearinghouse
showed that half of the guidelines reported no information
regarding funding sources or financial conflicts of interest
of the authors [27].
That COI can misinform healthcare decision makers is
widely recognized [30,31]. Omission of consideration for
COI can damage an organization’s reputation or require
time consuming processes of dealing with perceived influence of COI. Examples include guidelines developed
by the World Health Organization, the surviving sepsis
campaign and the Infectious Disease Society of America
Lyme Disease Guidelines [26,32-39]. Declaration and
management of COI is therefore of increasing importance
for medical professional societies and other organizations
developing practice guidelines [29,40,41]. Financial COI is
the best known type of COI and typically a result of direct
financial benefit related to topics discussed or products
recommended in guidelines. These personal financial
interests are not limited to employment, consultancies,
paid expert 15 testimony, stock holdings, endowments,
patents, royalties, honoraria, and in kind gifts (e.g. travel,
accommodation, meals, frequent flier miles). Indirect

Table 2 Definitions of conflicts of interest
A conflict of interest is a set of circumstances that creates a risk that
professional judgment or actions regarding a primary interest will be
unduly influenced by a secondary interest.[28] (IoM)
“A divergence between an individual’s private interests and his or her
professional obligations such that an independent observer might
reasonably question whether the individual’s professional actions or
decisions are motivated by personal gain, such as financial, academic
advancement, clinical revenue streams or community standing” [29]
“A financial or intellectual relationship that may impact an individual’s
ability to approach a scientific question with an open mind” [29].
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financial interests are a reality as academic advancement
can be related to topics discussed in guidelines. Direct
guideline funding by for-profit organizations is another
common problem and some authors have requested that
professional medical organizations reject all industry funding for practice guidelines [42].
Intellectual COI is another type of conflict [29] that is
increasingly recognized and results from a guideline group
member being invested in her/her intellectual work. Other
examples include authorship of original studies and peerreviewed grant funding directly related to recommendations under consideration. [29] Additional types of COI
include academic conflicts (e.g. competition for funding)
and conflicts related to clinical revenue streams (e.g., from
performing an advanced diagnostic procedure that is
under consideration for a recommendation).
Why are conflicted individuals not categorically excluded
from guideline development?

The biases resulting from COI may be conscious or unconscious [43] and may influence choices made throughout the
guideline development process, including conceptualization
of the question, choice of comparisons, interpretation of
the evidence and, in particular, drafting of the recommendations.[44] Under these circumstances why are conflicted
individuals not categorically excluded from guideline
development?
The most knowledgeable individuals can be conflicted
because of their expertise in the area of interest. These
“experts” may possess unique insight into appropriate
healthcare questions to ask in guidelines. But because of
their involvement in research they may have both financial and intellectual COIs whilst also possessing unique
insight into aspects of the existing evidence such as
study design and decisions made during conduct of studies. Such individuals may be difficult to replace because of
the unique insights they provide. The aim (and challenge)
should be to manage the potential COI appropriately ranging from informal consultation and exclusion from a
group to participation without influencing recommendations. Approaches to doing this have been described in a
recent policy of the American Thoracic Society[29]; an example is in a WHO guideline on Avian Influenza where
un-conflicted methodologists prepared evidence summaries, chaired the guideline committee and wrote the first
draft of the guideline.[45,46] A further implementation including a clearer separation of un-conflicted methodologists from the influence of potentially conflicted experts is
currently undertaken by the executive committee of the
American College of Chest Physicians Antithrombotic
Guidelines.[47] In this latter approach un-conflicted
methodologists lead the formulation of recommendations
in collaboration with experts who may be conflicted to a
degree that would not preclude them from participation.
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How should guideline developers deal with conflict of
interest?
Declaration of COI

Participants in guideline development should ideally submit written disclosures of all potential interests that may
cause a conflict of interest and disclosures should be made
prior to being involved in an official capacity. The individual can declare in writing: all known current and past
interests relevant to the subject and scope of the matter
for a number years prior to the date of declaration (many
organizations use a period of three years); and any conflicts of interest relevant to the subject and scope of the
matter that are expected to occur in the near future. Disclosure can be made through standard forms or a uniform
online process that could span across organizations. Updating as individualcircumstances warrant, and attest to
its accuracy and currency is important. All participants
(committee/group members and/or presenters) should be
asked and reminded to consider their own conflicts and
conflicts of others during discussions and decision making. Participants should abstain from discussion and voting if they or a sizable proportion of the other participants
identify a COI. The chair of the group should be free of
COI.
Review and management of COI

Those choosing participants for guideline development
should review disclosures before deciding on participants, and consider excluding participants if there is a
non-resolvable conflict of interest. The procedures (including step by step review and management) is best
clearly described and part of a policy. This policy should
involve independent review of COI and decision making
by committees. Ideally guideline developers will provide
group members with examples of COI management
from anonymous cases that describe appropriate methods of COI management.
Disclosure of COI to other group members

Once the members of a guideline group have been
assembled, COI of members should be identified and discussed before beginning deliberations. Individual participants (including project chairs and group members) should
label where COI bear on specific recommendations.
Recusal or excusal from certain decisions or
recommendations when appropriate

If groups involve members with (limited) COI, Chairs
and group members on a guideline group should ensure
that committees are reminded of the specific COI before
discussion of individual conclusions or recommendations on which those COI bear. This will allow recusal
from recommendations of those with important COI.
Group chairs can play an active role and excuse group
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members from discussions or decision-making on particular recommendations.
Procedures for handling disputes in COI resolution

An organization should develop and oversee the procedures and instruments used to disclose, review and resolve
COI, and should advise and assist chairs and organizers
where necessary. In instances where determination of COI
and actions taken to resolve COI are disputed, procedures
should be in place to address the matter.
Summary

In this first paper we have described target audiences for
guidelines, the criteria for choosing topics for guideline development (including acknowledging the current debate
about co-morbidities), group composition and group processes and the important procedural issue of managing conflicts of interest. In the next paper we move on to discuss
issues of identifying and synthesizing evidence: deciding
what type of evidence and outcomes to include in guidelines; integrating values into a guideline; incorporating economic considerations; synthesis, grading, presentation of
evidence; and moving from evidence to recommendations.
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